Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking disease progression, and evaluating the therapeutic efficacy of anti-dementia drugs. The radiotracers used in this imaging must be highly sensitive and specific for tau protein fibrils in the human brain. We developed a novel tau PET tracer, 
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ABSTRACT
Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking disease progression, and evaluating the therapeutic efficacy of anti-dementia drugs. The radiotracers used in this imaging must be highly sensitive and specific for tau protein fibrils in the human brain. We developed a novel tau PET tracer, demonstrated-compared to 18 F-THK5117-faster kinetics, higher contrast, and lower retention in subcortical white matter. Conclusion: 18 F-THK5351 is a useful PET tracer for early detection of neurofibrillary pathology in AD patients.
INTRODUCTION
Tau accumulation occurs in a stereotyped spatiotemporal manner at the intraneuronal and anatomical distribution levels in the brain and is associated with neuronal loss and cognitive impairment (1) (2) (3) (4) (5) . Because tau accumulation plays a key role in neurodegeneration and is considered to start before extensive neuronal loss emerges, tau-focused drug-discovery strategies for Alzheimer's disease (AD) are of particular interest (6, 7) . In efforts to accelerate drug discovery, there is growing demand for techniques to measure brain tau loads noninvasively. PET imaging of tau is expected to provide spatiotemporal information on the progression of tau pathology in the living brain. Therefore, this technique will facilitate accurate tauopathy diagnosis, precise assessment of disease severity and therapeutic efficacy, and patient enrolment for anti-tau therapeutic trials (8) (9) (10) .
Several putative tau PET tracers have been developed and tested in humans (11) (12) (13) (14) , and all of these tracers show elevated uptake in the hippocampus and temporal cortex of AD patients. We screened β-sheet-binding compounds and identified a series of compounds that preferentially bind to tau deposits in AD brains (15) (16) (17) . Through compound optimization, several 18 F-labeled arylquinoline derivatives were developed as candidate tau PET radiotracers (18 
MATERIAL AND METHODS

Radiosynthesis of Quinoline Derivatives
18
F-THK5351 was prepared from its tosylate precursor
-tosyloxy]propoxy] quinoline (THK5352) according to the previously described method for synthesizing 18 F-THK5105 and 
Small-Animal PET Studies
All animal experiment protocols were approved by the Laboratory Animal Care Committee of Tohoku University. In vivo PET studies were performed using male SLC:ICR mice, as described (24) .
Biodistribution Studies
Biodistribution was investigated after intravenous injection of 18 F-THK5351 or 18 F-THK5117 into male ICR mice as previously described (18) . Based on the biodistribution data from mice (%ID/g), we estimated the radiation dose and mass dose for humans.
Animal Toxicity Studies
A 14-day toxicity study involving a single-dose THK5351 test-article administration through intravenous injection in ICR mice was performed at Mitsubishi Chemical Medience Corporation (Tokyo, Japan), as described (18) .
Radiosynthesis for Clinical PET Study
18
F-THK5351, 18 F-THK5117, and 11 C-PiB were prepared at the Cyclotron and Radioisotope Center, Tohoku University. 18 F-THK5351 was radiosynthesized using a semi-automated system developed in-house.
No-carrier-added in DMSO (0.7 mL) was transferred into the reaction vial and stirred at 110°C for 10 min, and then aq. HCl (2 mol/L, 0.2 mL) was added to the reaction solution and stirred at 110°C for another 3 min. The reaction was then quenched with aq. AcOK (0.8 mol/L, 1 mL) and distilled water (7 mL), after which solid-phase extraction was performed using a Sep-Pak tC18 Plus cartridge (Waters). The trapped radioactive products were eluted using 60% EtOH, and then the eluate was mixed with H2O and subjected to semi-preparative HPLC separation under the same conditions as those described above. The HPLC fraction of 18 F-THK5351 was collected in glassware containing H2O (30 mL) and ascorbic acid (25%, 1.0 mL; NIPRO Pharma, Tokyo, Japan), and 18 F-THK5351 was isolated from the solution through solid-phase extraction performed using a Sep-Pak tC18 Plus cartridge. The ethanol eluate from the cartridge was transferred into a flask containing polysorbate-80 (5% in ethanol, 0.8 mL) and ascorbic acid (25%, 0.2 mL), and then the solution was evaporated to dryness. The radioactive residue was dissolved in saline and sterilized through filtration by using a Millex-GV Syringe Filter Unit (Millipore, Billerica, MA). 18 F-THK5117 was synthesized as described previously (20).
11
C-PiB was synthesized by using a loop-method with 11 C-methyl triflate, as reported (25) .
The radiochemical purity of the injectable solutions of 18 F-THK5351, 18 F-THK5117, and 11 C-PiB was >95%, and their specific activities were 254 ± 47, 357 ± 270, and 240 ± 48 GBq/mol, respectively.
Clinical PET Study Participants
Three AD patients and 3 healthy elderly study participants underwent 
Image Analysis
Standardized uptake value (SUV) images of 
Statistical Analysis
Pearson correlation coefficients were calculated to access the relationship between 3 H-labeled tracer binding and the amounts of insoluble protein.
Spearman correlation coefficients were calculated to access the relationship between tracer retentions in AD patients.
RESULTS
In Vitro Tracer Binding to Human Brain Tissues
In vitro saturation binding assays were conducted to measure the binding affinity of Fig. 1B) . The specific binding of THK5351 was also correlated with the level of insoluble tau (r = 0.71, P < 0.05), but not insoluble amyloid-β (r = -0.20, P = 0.63) or PiB (r = -0.10, P = 0.82), as observed for THK5117 (20). Furthermore, in vitro dissociation assays performed using brain white-matter homogenates revealed that THK5351 dissociated from white matter more rapidly than THK5117 did ( Fig. 2A) .
In Vitro Autoradiography in Human Brain Sections
To further evaluate binding selectivity and signal-to-background ratio, in vitro autoradiography was performed using H-THK5351 signals were detected in white matter (Fig. 2B) . 3 
H-THK5351
showed higher cortical-to-white matter binding ratio than 3 H-THK5117 did (Fig.   2C ). (Fig. 3) . However, 
Pharmacokinetics in Mice
Brain pharmacokinetics of 18 F-THK5351 in normal mice were investigated using a small-animal PET scanner. Although the peak brain uptake of 18 F-THK5351 was slightly lower than that of 18 F-THK5117, 18 F-THK5351 entered the brain immediately after intravenous injection and showed faster washout from the brain than 18 F-THK5117 did ( Fig. 4 ; Suppl. Table 2 ). No marked radiotracer retention in bone was observed after 18 F-THK5351 was injected into mice.
Animal Acute-Toxicity Studies
At 0.1 and 1 mg/kg dosages under our study conditions, no animals died and no treatment-related changes in any animal were noted in clinical observations, bodyweight measurement, and pathological examination.
Dose Estimates for Humans
18
F-THK5351 radiation exposure was estimated using the biodistribution data from mice (Suppl. Table 2 ). The resultant whole-body effective dose equivalents were 14.4 μSv/MBq (male) and 18.4 μSv/MBq (female) (Suppl. Table 3 ). The organ doses for 18 F-THK5351 were comparable to those associated with other common radiotracers.
Clinical PET Study
The SUV time-activity curves from F-THK5351 retention was observed in the medial temporal cortex of elderly healthy control subjects (Fig. 6A) . 18 F-THK5351 showed higher contrast and lower subcortical white-matter retention than 18 F-THK5117 did (Fig. 6B) . (Fig. 7) . Our preclinical studies demonstrated that the pharmacokinetic profiles of the S-enantiomers of arylquinoline derivatives were more favorable than those of the R-enantiomers (20, 24) . Therefore, optical purification should additionally contribute toward improving THK5351 pharmacokinetics. Our preclinical data revealed that 18 F-THK5351 shows high and selective binding ability for tau aggregates, low binding affinity for white matter, and rapid pharmacokinetics, which collectively resulted in the signal-to-background ratio of THK5351 being higher than that of both THK5105 and THK5117. Furthermore, autoradiography performed on human brain sections also confirmed that THK5351 does not bind to amyloid, α-synuclein, and TDP43 deposits (data not shown), which suggests that THK5351 binds to tau protein fibrils with high selectivity.
As observed in our previous 18 F- THK5105 and 18 F-THK5117 PET studies 
